1. Molecular correlates of durable remission, adaptive resistance, or primary resistance were identified in older patients with AML receiving venetoclax-based combinations.
2. Determinants of anti-PD-1 response and resistance were studied in clear cell renal cell carcinoma patients.
3. ADAPTeR is a prospective phase II study of nivolumab in treatment-naive patients.
很遗憾,由于提供的文章只有标题和部分摘要,并没有足够的信息来进行详细的批判性分析。请提供完整的文章或更多相关信息,以便进行更深入的分析。